Metabolic response as assessed by<sup>18</sup>F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Harrison, Douglas J.; Chi, Yueh‐Yun; Tian, Jing; Hingorani, Pooja; Mascarenhas, Leo; McCowage, Geoffrey; Weigel, Brenda; Venkatramani, Rajkumar; Wolden, Suzanne L.; Yock, Torunn I.; Rodeberg, David A.; Hayes‐Jordan, Andrea; Teot, Lisa A.; Spunt, Sheri L.; Meyer, William H.; Hawkins, Douglas S.; Shulkin, Barry L.; Parisi, Marguerite T.

doi:10.1002/cam4.3667

Cited by 21 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the combination of tumor volume, high 18 F-FDG uptake and restricted diffusion can predict outcomes. However, Harrison et al [ 33 ] could not demonstrate a correlation between SUV max or complete metabolic response with survival in rhabdomyosarcoma. No published studies investigate rhabdomyosarcoma tumor sub-volumes using our voxel-by-voxel-based approach for SUV and ADC values.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma

Maennlin¹,

Chaika²,

Gassenmaier³

et al. 2022

Pediatr Radiol

View full text Add to dashboard Cite

Background Cross-sectional imaging-based morphological characteristics of pediatric rhabdomyosarcoma have failed to predict outcomes. Objective To evaluate the feasibility and possible value of generating tumor sub-volumes using voxel-wise analysis of metabolic and functional data from positron emission tomography/magnetic resonance imaging (PET/MR) or PET/computed tomography (CT) and MRI in rhabdomyosarcoma. Materials and methods Thirty-four examinations in 17 patients who received PET/MRI or PET/CT plus MRI were analyzed. The volume of interest included total tumor volume before and after therapy. Apparent diffusion coefficients (ADC) and standard uptake values (SUV) were determined voxel-wise. Voxels were assigned to three different groups based on ADC and SUV: “viable tumor tissue,” “intermediate tissue” or “possible necrosis.” In a second approach, data were grouped into three clusters using the Gaussian mixture model. The ratio of these clusters to total tumor volume and changes due to chemotherapy were correlated with clinical and histopathological data. Results After chemotherapy, the proportion of voxels in the different groups changed significantly. A significant reduction of the proportion of voxels assigned to cluster 1 was found, from a mean of 36.4% to 2.5% (P < 0.001). There was a significant increase in the proportion of voxels in cluster 3 following chemotherapy from 24.8% to 81.6% (P = 0.02). The proportion of voxels in cluster 2 differed depending on the presence or absence of tumor recurrence, falling from 48% to 10% post-chemotherapy in the group with no tumor recurrence (P < 0.05) and from 29% to 23% (P > 0.05) in the group with tumor recurrence. Conclusion Voxel-wise evaluation of multimodal data in rhabdomyosarcoma is feasible. Our initial results suggest that the different distribution of sub-volumes before and after therapy may have prognostic significance.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma

Maennlin¹,

Chaika²,

Gassenmaier³

et al. 2022

Pediatr Radiol

View full text Add to dashboard Cite

show abstract

“…Once pathologic confirmation of the diagnosis is available, further staging imaging with PET is obtained with a focus upon regional nodal involvement and distant spread of tumor, though the sensitivity for nodal involvement is not optimal [ 24 , 25 ]. Use of PET for prognostication has not proven clinically valid [ 26 ]. Most patients also undergo a bone marrow biopsy along with cerebrospinal fluid (CSF) sampling via lumbar puncture if there is parameningeal disease [ 9 ].…”

Section: Resultsmentioning

confidence: 99%

Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma

Frankart

Breneman

Pater

2021

Cancers

View full text Add to dashboard Cite

The use of radiation therapy is an important part of multimodality treatment for rhabdomyosarcoma. The specific doses, treatment volumes, and techniques used in radiation therapy can vary dramatically based upon a number of factors including location, tumor size, and molecular characteristics, resulting in complex decisions in treatment planning. This article reviews the principles of evaluation and management for head and neck rhabdomyosarcoma including a summary of the historical studies upon which current management is based.

show abstract

“…FDG PET-CT has been shown to be useful in monitoring response to therapy for pediatric rhabdomyosarcomas, although it has not been as well studied in adults [ 84 ]. However, the magnitude of metabolic activity pre-treatment does not predict outcome in rhabdomyosarcoma in children [ 85 ].…”

Section: Sarcomasmentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Fine

Covington

Koppula

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, therapeutic assessment, restaging and surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, the potential pitfalls and nuances that characterize these applications, and guidelines for image interpretation. Tumor-specific clinical information and representative PET-CT images are provided. The current, sixth article in this series addresses PET-CT in an evaluation of aggressive cutaneous malignancies, sarcomas and neuroendocrine tumors. A discussion of the role of FDG PET for all types of tumors in these categories is beyond the scope of this review. Rather, this article focuses on the most common malignancies in adult patients encountered in clinical practice. It also focuses on Food and Drug Agency (FDA)-approved and clinically available radiopharmaceuticals rather than research tracers or those requiring a local cyclotron. This information will serve as a guide to primary providers for the appropriate role of PET-CT in managing patients with cutaneous malignancies, sarcomas and neuroendocrine tumors. The nuances of PET-CT interpretation as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees, are also addressed.

show abstract

Metabolic response as assessed by¹⁸F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 21 publications

References 47 publications

Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma

Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma

Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Contact Info

Product

Resources

About

Metabolic response as assessed by18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 21 publications

References 47 publications

Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma

Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma

Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Contact Info

Product

Resources

About

Metabolic response as assessed by¹⁸F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee